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ROUTINE AND RECOMMENDED VACCINATIONS 
FOR TRAVELLERS 
EWA DUSZCZYK, EWA TALAREK 1 
INTRODUCTION 
Travels, especially to the tropics, are connected with the risk acquiring infectious 
diseases, some of which may  be fatal. Vaccinations may protect the traveller. 
Epidemiological and personal risk factors should be considered when planning such 
vaccinations.  
The number of traveling people in the world has been increasing since 1990. The 
World Tourism Organization estimates that this number will exceed one billion in 2010 
(1). Particularly the travel to developing, exotic countries is connected with this health 
hazard, and  it depends on the region of the world, on the mode and duration of travel.  
The traveller should be informed about the epidemiological situation in the 
destination country and about the necessary preventive measures, among them the 
vaccinations. Important is also the behaviour of the traveller and following the hygiene 
rules.  
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Neglecting these measures may result in a serious,  possibly fatal disease. 
Obtaining a specialist’s advice from a Travel Clinic is useful before going to the 
tropics. 
Information about prophylctic measures can be also obtained from the in sanitary-
epidemiological stations, from the internet service of WHO,  and in Poland - from the 
Institute of Maritime and Tropical Medicine in Gdynia. Such information should also be 
offered by travel agencies.  
In recommending vaccinations, the following factors should be considered: 
epidemiological risk in a given area, age and the general health condition of the 
traveller,  immunizations taken previously and their possible adverse effects (2, 3, 4). 
The costs of vaccinations used before travels are usually not reimbursed by the national 
health systems. 
Vaccinations if necessary should be started 6-8 (not later than 4) weeks before the 
planed departure. 
Vaccination against yellow fever 
The only vaccination  required by the International Health Regulations is yellow 
fever vaccination for travel to certain countries in sub-Saharan Africa and tropical South 
America. 
The following countries require vaccination certificate from all travellers for entry 
to: Benin, Burkina Faso, Chad, Congo, Cŏte d`Ivoire (Ivory Coast), Democratic 
Republic of Congo, French Guiana, Gabon, Ghana, Liberia, Mali, Mauritania 
(exception: not required for travellers from a non-endemic zone who stay less than 2 
weeks), Niger, Rwanda, Togo, Saó Tomé and Principe, Sierra Leone. Country 
requirements are subject to change at any time. Updated information  on endemic 
countries and  regulations can be obtained from the WHO and CDC websites: 
http://www.who.int, http://www.cdc.gov/travel. 
Yellow fever is a severe, potentially fatal disease caused by viruses, transmitted by 
mosquito bites. Prevention is achieved by a single dose of vaccine, given at least 10-14 
days before departure. Stamaril by Sanofi Pasteur is the only available vaccine (also in 
Poland). It contains a live, attenuated yellow fever virus, strain Dakar 17. It is given 
subcutaneously or intramuscularly. It can be administered with other vaccines during 
one visit, with separate syringe and to another part of body. A single dose confers 
immunity lasting 10 years or more (4, 5). If a person is at continued risk of yellow fever 
infection, a booster dose is needed every 10 years. The vaccination should be 
documented in the “International Certificate of Vaccination or Prophylaxis”. The 
international yellow fever vaccination certificate is valid 10 days after vaccination and 
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remains valid for 10 years. Vaccination and documentation must be performed only in 
institutions licensed by WHO. Vaccination is not recommended in pregnant women (but 
can be administered if indicated), breastfeeding women, in persons with anaphylaxis for 
eggs, immunocompromised patients and children younger than 12 months. In 1960 it 
was stated that in special situations yellow fever vaccine can be given to children from 
the 9th month of life. A person who was not vaccinated and has no valid cerificate 
before entering one of the above listed countries may be arrested or heavily fined (2, 5). 
If the vaccination is contraindicated for medical reasons, a medical certificate is 
required for exemption (in English and French).  
Areas where yellow fever virus is present far exceed those officialy reported. The 
absence of a requirement for vaccination does not imply that there is no risk of exposure 
to yellow fever in a country. 
Vaccination against viral hepatitis A 
Viral hepatitis A occurs as an endemic disease in countries of poor sanitary 
conditions. It the most frequent disease acquired during travel to the developing 
countries. Average incidence is 300/100 000/month of travel. The risk for hepatitis A is 
100 times higher than for typhoid fever or cholera. A stay in four stars hotel does not 
decrease the risk. Prophylactic vaccination is recommended at least 4 weeks before 
departure. Hepatitis A vaccines contain hepatitis A virus inactivated with formaldehyde 
and adsorbed to aluminum hydroxide as adjuvant. The vaccine should be administered 
intramuscularly in the deltoid muscle. A single dose prevents hepatitis A for a year. For 
a long-term protection a second dose should be given 6-12 months after the first one. 
No boosters are recommended. Vaccines can be used in children older than 12 months. 
They can be administered separately or with other vaccines  during the same visit (in  
separate syringes  and distant sites).  
Hepatitis A vaccines licensed and available in Poland are presented in Table 1. 
Havrix Junior is for persons younger than 18 years, Vaqta 25U/0,5ml – younger 
than 17 years. Avaxim is used in the same dose in children and adults (7). All hepatitis 
A vaccines are immunogenic and effective. Seroconversion was found in 79% of 
vaccinated 13 days after a first dose and in 99% after a month. A single dose of hepatitis 
A vaccine can also be administered as post exposure prophylaxis instead of 
immunoglobulin, as soon as possible, not later than 14 days after exposure(8). 
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Table 1. Hepatitis A vaccines 
Vaccine Dose Manufacturer 
Avaxim 169 U/0,5ml Sanofi Pasteur 
Havrix Junior 720 U ELISA/0,5ml GSK 
Havrix 1440 U ELISA/1ml GSK 
Vaqta 25 U/0,5ml MSD 
Vaqta 50 U/1ml MSD 
Table 2. Hepatitis B vaccines 
Vaccine Manufacturer 
Engerix B GSK 
HBVax II MSD 
HBVax PRO MSD 
Euvax B LG Life Sciences 
Hepavax-Gene Crucell 
 
Vaccination against viral hepatitis B 
Holidays and business  travels are connected with risk of traffic or sport injuries. In 
hepatitis B endemic countries hospitalizations, especially with parenteral procedures, 
may be a source of hepatitis B virus (HBV) infection. Sex contacts and intravenous drug 
use are also a possible source of it  and the risk for HBV infection is much higher than 
for HIV infection. The consequences of HBV infection are well known. Vaccination is 
the best prophylactic measure. Vaccines licensed in Poland are listed in Table 2. All 
those vaccines contain hepatitis B surface (HBs) antigen produced by recombinant 
DNA technology and they are free of any human or animal tissue. 
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Vaccines are produced in doses for children and for adults. Pediatric dose is used in 
children younger than 15 years. Primary vaccination consists of  3 intramuscular doses 
of hepatitis B vaccine administered at 0, 1, and 6 months. There is a rapid immunization 
schedule (0, 7, 21 days and 12 months), licensed only for Engerix B in adults. 
According to CDC recommendations boosters are not routinely administered. In persons 
not previously immunized against hepatitis A and hepatitis B combined vaccine can be 
used. Twinrix Adult (GSK) contains 720 IU of hepatitis A virus and 20µg of 
recombinant HBs antigen. Primary vaccination consists of 3 doses at 0, 1 and 6 months. 
Rapid immunization schedule is also licensed: 0, 7, 21 days and 12 months (2, 4, 7). 
Vaccination against typhoid fever 
The disease is caused by Salmonella typhi. Routine vaccination against typhoid 
fever has not been used in Poland since 1968. Infections with Salmonella typhi are 
common in the tropics. Transmission is by fecal-oral route. The highest risk for 
infection is in India. It is estimated that incidence there is 30/100 000 travelers (2). 
Travelers have acquired typhoid fever even during brief visits of less than 1 week to 
countries where the disease is endemic. Vaccination is recommended for travelers to 
Asia, Africa and South America. It is particularly recommended for those who will be 
traveling in smaller cities, villages, and rural areas off the usual tourist itineraries, where 
food and beverage choices may be more limited. The most commonly used vaccine is 
Typhim Vi (Sanofi Pasteur). It contains polysaccharide antigen. A single dose provides 
3 years lasting protection. The vaccine is not immunogenic in children younger than 2 
years (there is no vaccine for children <2 years). In Poland 2 typhoid fever vaccines are 
produced (by Biomed Krakow): Ty - containing suspension of bacilli Salmonella typhi 
inactivated with formaldehyde and TyT – with tetanic toxoid. Primary vaccination 
consists of 3 doses: 0, 4-6 weeks, 12 months. In some countries combine vaccines 
against typhoid fever and hepatitis A (e.g. Hepatyrix, GSK) and live attenuated oral 
vaccine against typhoid fever (Oral Typhoid Vaccine Ty21a, Vivotif Berna) are 
available. 
Vaccination against poliomyelitis 
Polio vaccination is routinely made in children in most countries worldwide. In 
Poland the last dose is administered in the 6th year of life. Vaccination is recommended 
in persons older than 30 years traveling to endemic regions: sub-Saharan Africa, India. 
There are two kinds of vaccines: OPV – live attenuated oral vaccine and IPV – 
inactivated vaccine, for intramuscular administration. Currently only IPV is used in 
travel medicine (4). In Poland inactivated vaccine Imovax polio (GSK) is used. It is safe 
also in immunocompromised patients. Vaccination is valid for 10 years. 
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Vaccination against diphtheria and tetanus 
Diphtheria and tetanus vaccination is a routine vaccination  (8). The last dose is 
administered in the 19th year of life. Diphtheria has been eliminated in most countries, 
but it still occurs. During diphtheria outbreak in the ex-Soviet Union countries in 1990-
1997 there were fatal cases among non-immunized tourists (2). 99% cases of tetanus 
occur in the tropics. If the last diphtheria and tetanus vaccination was done 9-10 years 
before the travel, it is recommended to administer booster dose of TD vaccine. 
Immunity is then prolonged for the next 10 years (5). 
Vaccination against meningococcal disease 
Invasive meningococcal disease (IMD) caused by Neisseria meningitidis is 
characterized by sudden onset, rapid course and potential fatal outcome. For most cases 
5 serogroups are responsible: A, B, C, W135, Y; distribution of them depends on the 
geographic region. Vaccination is recommended for children and adults traveling to 
meningitis belt in sub-Saharan Africa (from Senegal in the west to Ethiopia in the east) 
during the dry season (December through June). Saudi Arabia requires that visitors – 
Hajj or Umra pilgrims - have a certificate of vaccination with a tetravalent (A,C,Y,W-
135) meningococcal vaccine before entering (4, 5). Before travel to other 
endemic/epidemic regions vaccination can be indicated depending on current 
epidemiologic situation. Information is available on the CDC website 
http://www.cdc.gov/travel. Meningococcal vaccines licensed in Poland are listed in 
Table 3. Polysaccharide vaccine is not efficient in children younger than 2 years. 
Conjugate vaccines can be used in children from the 2nd month of life. There is no 
vaccine against meningococcal serogroup  B. 
Table 3. Meningococcal vaccines 
 
Vaccine Type of vaccine Manufacturer 
Meningo A+C polysaccharide Sanofi Pasteur 
NeisVac-C Conjugated with tetanic toxoid Baxter 




Vaccination against tick borne encephalitis (TBE) 
TBE is an endemic disease occurring in some regions of 27 European countries. 
Non specific prophylactic methods (avoidance of exposure to tick bites, proper clothing, 
repellents) are insufficient. Vaccination provides protection and it is recommended for 
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person residing and travelling to endemic regions (9). Vaccines FSME-Immun and 
FSME-Immun Junior (Baxter) are available in Poland. Pediatric dose is for 1-16 years 
old children. Primary vaccination consists of 3 doses: 0, 1-3, 9-12 months. Vaccination 
should be started before tick activity season (late winter, early spring). Rapid 
vaccination schedule is also licensed: 0, 14 days and 12 months. For long-term 
immunity booster doses are required: first after 3 years and next ones every 5 years 
(every 3 years for persons older than 65 years).  
Other vaccinations 
Vaccination against cholera is currently recommended only for persons working in 
high risk conditions (4). Vaccine Verorab (Sanofi Pasteur) against rabies is used as a 
pre-exposure prophylaxis only in persons with occupational contacts with animals and 
in cave explorers. Vaccination includes then 3 primary doses  at 0, 7, 28 days and 
booster after a year. Vaccine against Japanese encephalitis is not available in Poland. 
For travellers to Asia, particularly Middle and Far East, influenza vaccination is 
recommended. Persons older than 65 years should be vaccinated against pneumococcal 
disease (vaccines: Pneumo23, Sanofi Pasteur and Pneumovax, MSD) (2, 7). 
The important problem in travel medicine is malaria. So far there is no sufficient 
vaccine against that dangerous disease. Prophylaxis is based on drugs. Choice of 
prophylactic drug depends on the region, length of stay and drug-resistance of 
plasmodia (4, 5). Information and advice are given in outpatient clinics of tropical 
diseases. 
Prevention of travellers` diarrhea (TD) 
Diarrhoea affects 20-50% of travellers to the tropics. The most common cause is 
enterotoxicogenic Escherichia coli (ETEC). The course is usually afebrile, with loose 
stools (no blood or mucus) and cramps. Treatment is symptomatic with oral 
rehydration, proper diet, probiotics, chemiotherapeutics are not usually recommended. 
TD is generally self-limited and lasts 3-4 days, but persistent symptoms may occur in a 
small percentage of travelers. Prevention includes food and beverage selection. Foods 
should be freshly cooked or fried and served hot. Foods washed in non-potable water 
such as salads, raw fruits and vegetables should be avoided. Bottled, canned and 
carbonated beverages may be safely consumed (with noi ice cubs), as well as boiled 
beverages. Consumption of food or beverages from street vendors poses a particularly 
high risk. It is important to wash hands with soap before meals and wash teeth with 
boiled water (5). 
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SUMMARY 
Travel risks should not be neglected. Health hazard is unprofitable. Adequately 
planned, individually adjusted prophylaxis makes travel not only pleasant, but safe as 
well.  
It is worth to emphasize that fever in person coming back from the tropics requires 
quick exclusion (or confirmation) of malaria. 
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